An update from the PURPOSE 2 trial focused on adherence and pharmacokinetics data for lenacapavir, used to prevent HIV.

RBC Capital analyst Brian Abrahams raised the firm’s price target on Gilead (GILD) to $84 from $81 but keeps a Sector Perform rating on the ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) today and set a price target of $84.00.

AUSTIN, Texas, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer’s ...

The scope of Gilead Sciences' recent round of layoffs is coming into clearer view with the revelation that the company is ...

This report explores the benefits and challenges of NHS-industry partnerships aiming to catalyse improvements in the health ...

STEM South West is back for its sixth year, promising to be the biggest and best one yet - this time taking over Cork City ...

But that could soon change for the better thanks to companies, like Cardiol Therapeutics (NASDAQ: CRDL), Abbott Laboratories (NYSE: ABT), Gilead Sciences (NASDAQ: GILD), Medtronic (NYSE: MDT) and ...

Veterinary and pet industry leaders play a crucial role in keeping their practices and businesses running smoothly. Their ...

The preclinical data presented at ACR Convergence underscore the exceptional potential of our targeted protein degradation strategy compared to kinase inhibition for both BTK and IRAK4, which are ...

US antiviral giant Gilead Sciences on Friday unveiled two-and-a-half-year interim analysis from the ongoing Phase III ASSURE ...